JP7671308B2 - Ａｔｐ結合部位に結合するイソインドリン誘導体 - Google Patents

Ａｔｐ結合部位に結合するイソインドリン誘導体 Download PDF

Info

Publication number
JP7671308B2
JP7671308B2 JP2022569300A JP2022569300A JP7671308B2 JP 7671308 B2 JP7671308 B2 JP 7671308B2 JP 2022569300 A JP2022569300 A JP 2022569300A JP 2022569300 A JP2022569300 A JP 2022569300A JP 7671308 B2 JP7671308 B2 JP 7671308B2
Authority
JP
Japan
Prior art keywords
formula
methyl
piperazin
dihydroxy
isoindolin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022569300A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023511229A (ja
JP2023511229A5 (https=
Inventor
ブラッグ，ジュリアン
ロフェイ，ジョナソン・リチャード・アンソニー
ウィンシップ，ポール・コリン・マイケル
ラングレー，ガレス・ウィリアム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neophore Ltd
Original Assignee
Neophore Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2000789.4A external-priority patent/GB202000789D0/en
Priority claimed from GBGB2003559.8A external-priority patent/GB202003559D0/en
Application filed by Neophore Ltd filed Critical Neophore Ltd
Publication of JP2023511229A publication Critical patent/JP2023511229A/ja
Publication of JP2023511229A5 publication Critical patent/JP2023511229A5/ja
Application granted granted Critical
Publication of JP7671308B2 publication Critical patent/JP7671308B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G01N2333/922—Ribonucleases (RNAses); Deoxyribonucleases (DNAses)

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2022569300A 2020-01-20 2021-01-20 Ａｔｐ結合部位に結合するイソインドリン誘導体 Active JP7671308B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB2000789.4A GB202000789D0 (en) 2020-01-20 2020-01-20 Novel probe molecules
GB2000789.4 2020-01-20
GBGB2003559.8A GB202003559D0 (en) 2020-03-11 2020-03-11 Novel probe molecules
GB2003559.8 2020-03-11
PCT/GB2021/050122 WO2021148786A1 (en) 2020-01-20 2021-01-20 Isoindoline derivatives which bind to an atp binding site

Publications (3)

Publication Number Publication Date
JP2023511229A JP2023511229A (ja) 2023-03-16
JP2023511229A5 JP2023511229A5 (https=) 2025-04-03
JP7671308B2 true JP7671308B2 (ja) 2025-05-01

Family

ID=74285509

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022569300A Active JP7671308B2 (ja) 2020-01-20 2021-01-20 Ａｔｐ結合部位に結合するイソインドリン誘導体

Country Status (7)

Country Link
US (1) US12517130B2 (https=)
EP (1) EP4093731A1 (https=)
JP (1) JP7671308B2 (https=)
CN (1) CN115397811B (https=)
AU (1) AU2021211925A1 (https=)
CA (1) CA3168495A1 (https=)
WO (1) WO2021148786A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024528693A (ja) * 2021-07-19 2024-07-30 ネオフォア・リミテッド 阻害剤化合物

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021211925A1 (en) 2020-01-20 2022-08-25 Neophore Limited Isoindoline derivatives which bind to an ATP binding site
GB202008201D0 (en) 2020-06-01 2020-07-15 Neophore Ltd Inhibitor compounds
GB202307924D0 (en) * 2023-05-26 2023-07-12 Neophore Ltd Inhibitor compounds
CN117586174B (zh) * 2024-01-19 2024-05-10 中国药科大学 用于诊断结直肠癌的近红外荧光探针及其制法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015038649A1 (en) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2019118830A1 (en) 2017-12-14 2019-06-20 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0202133D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Novel compounds
JP2008540395A (ja) 2005-05-03 2008-11-20 ファイザー・インク アミドレソルシノール化合物
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
JP5410285B2 (ja) 2006-10-12 2014-02-05 アステックス、セラピューティックス、リミテッド 医薬化合物
JP5518478B2 (ja) 2006-10-12 2014-06-11 アステックス、セラピューティックス、リミテッド 医薬化合物
WO2009060835A1 (ja) 2007-11-05 2009-05-14 Kyoto University 新規ユビキリン結合性小分子
GB0806527D0 (en) 2008-04-11 2008-05-14 Astex Therapeutics Ltd Pharmaceutical compounds
KR102668696B1 (ko) 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
US20210275630A1 (en) 2016-04-18 2021-09-09 Phoremost Limited Inactivation of dna repair as an anticancer therapy
MA45670A (fr) 2016-07-13 2019-05-22 Vertex Pharma Procédés, compositions et kits pour augmenter l'efficacité d'édition du génome
EP3568128B1 (en) 2017-01-12 2022-07-06 The University of Kansas Hsp90b n-terminal isoform-selective inhibitors
WO2019014600A1 (en) 2017-07-13 2019-01-17 Plex Pharmaceuticals, Inc. TREATMENT OF ASSOCIATION FOR THE TREATMENT OF CANCER
EP3773670A4 (en) 2018-04-05 2022-03-09 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof
CA3099155A1 (en) 2018-05-14 2019-11-21 Nuvation Bio Inc. Anti-cancer nuclear hormone receptor-targeting compounds
US11026963B2 (en) 2018-07-11 2021-06-08 Rubedo Life Sciences, Inc. Senolytic compositions and uses thereof
GB201819126D0 (en) 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
AU2021211925A1 (en) 2020-01-20 2022-08-25 Neophore Limited Isoindoline derivatives which bind to an ATP binding site
GB202008201D0 (en) 2020-06-01 2020-07-15 Neophore Ltd Inhibitor compounds
GB202110373D0 (en) 2021-07-19 2021-09-01 Neophore Ltd Inhibitor compounds
GB202300881D0 (en) 2023-01-20 2023-03-08 Neophore Ltd Inhibitor compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015038649A1 (en) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2019118830A1 (en) 2017-12-14 2019-06-20 Tarveda Therapeutics, Inc. Hsp90-targeting conjugates and formulations thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024528693A (ja) * 2021-07-19 2024-07-30 ネオフォア・リミテッド 阻害剤化合物

Also Published As

Publication number Publication date
AU2021211925A1 (en) 2022-08-25
CN115397811A (zh) 2022-11-25
CA3168495A1 (en) 2021-07-29
CN115397811B (zh) 2025-05-23
EP4093731A1 (en) 2022-11-30
JP2023511229A (ja) 2023-03-16
US12517130B2 (en) 2026-01-06
US20230061002A1 (en) 2023-03-02
WO2021148786A1 (en) 2021-07-29

Similar Documents

Publication Publication Date Title
JP7671308B2 (ja) Ａｔｐ結合部位に結合するイソインドリン誘導体
CN103819486B (zh) 标记血清糖原磷酸化酶浓度水平的光亲和标记探针分子、其制备方法及医药用途
US6207831B1 (en) Fluorescent dyes (AIDA) for solid phase and solution phase screening
De León-Rodríguez et al. Highly regioselective N-trans symmetrical diprotection of cyclen
CN113646306A (zh) 雌激素受体降解protac
JP7523166B2 (ja) コロナウイルス３ｃｌプロテアーゼを標的とするｖｈｌリガンドに基づくｐｒｏｔａｃ、およびその調製方法と応用
JP2012508248A (ja) ベンゾアセピン誘導体の合成方法
Lin et al. Deprotection of N-tert-butoxycarbonyl (Boc) groups in the presence of tert-butyl esters
Angelici et al. Synthesis of imidazolidin-2-one-4-carboxylate and of (tetrahydro) pyrimidin-2-one-5-carboxylate via an efficient modification of the Hofmann rearrangement
Guarna et al. Synthesis of a new enantiopure bicyclic γ/δ-amino acid (BTKa) derived from tartaric acid and α-amino acetophenone
Wang Synthesis and properties of N-acetimidoyl derivatives of glycine and sarcosine
BR112020010149A2 (pt) derivado de pirimidina sulfamida e método de preparação e aplicação médica
EP1923397B1 (en) Fluorinated amino acids and peptides
Cui et al. Synthesis of (1 R, 4 R)-2, 5-diazabicyclo [2.2. 1] heptane derivatives by an epimerization–lactamization cascade reaction
JP6670502B2 (ja) 神経伝達物質受容体のリガンドスクリーニングシステムの開発
JP3851706B2 (ja) 蛍光性基含有カルボジイミド化合物
EP0808829A1 (en) Fluorescent group-containing carbodiimide compound
Moloney et al. Synthesis and serotonergic activity of a series of 2-(N-benzyl) carboxamido-5-substituted-N, N-dimethyltryptamine derivatives: novel antagonists for the vascular 5-HT 1B-like receptors
KR101278118B1 (ko) 다불소알킬기를 가진 트리아졸릴쿠마린 유도체, 그 제조방법 및 그의 용도
CN111606888B (zh) 吡咯类衍生物及其制备方法与应用
Sasaki et al. Convenient synthesis of 2, 3'-imino-1-(. beta.-D-lyxofuranosyl) uracil and its derivatives using azide ion
Gao et al. A new cleavable 4-hydroxyl-3, 5-di-tert butyl benzyl isocyanide in the Ugi tetrazole reaction
JP2009514865A (ja) 有糸分裂キネシン阻害剤
Huber et al. Application of the concept of oxime library screening by mass spectrometry (MS) binding assays to pyrrolidine-3-carboxylic acid derivatives as potential inhibitors of γ-aminobutyric acid transporter 1 (GAT1)
CN111132983A (zh) 一种异喹啉磺酰衍生物的晶型及其制备方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231027

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241025

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241211

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250325

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250415

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250418

R150 Certificate of patent or registration of utility model

Ref document number: 7671308

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150